Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

Item

http://www.wikidata.org/entity/Q45914699

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@en

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@nl

type

Item

label

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@en

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@nl

prefLabel

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@en

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@nl

P1476

Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.

@en

P2093

Andrew Aylsworth

http://www.w3.org/2001/XMLSchema#string

Arinze Nkemdirim Okere

http://www.w3.org/2001/XMLSchema#string

Cody VanNorman

http://www.w3.org/2001/XMLSchema#string

Zachary Dean

http://www.w3.org/2001/XMLSchema#string

P2860

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving!

P304

1202-1208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028014540450

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24951310

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes